Generic Medicine Info
Indications and Dosage
Prophylaxis of cluster headache, Prophylaxis of migraine
Adult: Initially, 0.5 mg, increase gradually as necessary. Maintenance: 1.5 mg daily as a single dose at night or in 3 divided doses. Max: 4.5 mg daily (max ≤3 mg/dose).
Child: ≥2 yr Initially, 0.5 mg. May increase gradually up to 1.5 mg daily in divided doses (max 1 mg/dose).
Renal Impairment
Dose adjustment may be needed.
Hepatic Impairment
Dose adjustment may be needed.
May be taken with or without food.
Special Precautions
Patient w/ angle-closure glaucoma, urinary retention, epilepsy. Avoid abrupt withdrawal. Renal and hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Increased appetite, nausea, wt gain, drowsiness, dizziness, dry mouth, fatigue, muscle pain or cramps, heavy or restless legs, fluid retention, facial flushing, reduced libido, exacerbation of epilepsy, dreaming, hepatic injury.
Patient Counseling Information
This drug may cause drowsiness, somnolence and dizziness, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor hepatic function (prolonged use), wt gain, BP.
Symptoms: Drowsiness, dizziness, hypotension, dry mouth, confusion, excitatory states (in childn), ataxia, nausea, vomiting, dyspnoea, cyanosis, tachycardia, convulsions (particularly in childn), coma, and resp paralysis. Management: Symptomatic treatment. Perform gastric lavage followed by admin of activated charcoal. Convulsions may be treated w/ short-acting barbiturates or benzodiazepines.
Drug Interactions
Enhances the central effects of sedatives, hypnotics, antihistamines including certain common cold preparations. May reduce the efficacy of cisapride. MAOIs may prolong or intensify the anticholinergic effect of pizotifen.
Food Interaction
Enhances the CNS effects of alcohol.
Description: Pizotifen is a sedating antihistamine which is known to inhibit the reuptake of serotonin by blood platelets, thereby preventing loss of tone of intracranial vessels. It has weak antimuscarinic properties and it also antagonises the action of tryptamine.
Absorption: Well absorbed from the GI tract. Absolute bioavailability: Approx 78%. Time to peak plasma concentration: Approx 5 hr.
Distribution: Extensively and rapidly distributed throughout the body. Volume of distribution: 833 L (pizotifen); 70 L (N-glucuronide). Plasma protein binding: >90%.
Metabolism: Extensively metabolised in the liver via glucuronidation.
Excretion: Via urine, mainly as metabolites; faeces (approx 18%). Elimination half-life: Approx 23 hr (N-glucuronide conjugate).
Store between 15-30°C. Protect from light and moisture.
MIMS Class
Antimigraine Preparations
ATC Classification
N02CX01 - pizotifen ; Belongs to the class of other antimigraine preparations.
Anon. Pizotifen. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/05/2016.

Buckingham R (ed). Pizotifen. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/05/2016.

Joint Formulary Committee. Pizotifen. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/05/2016.

Disclaimer: This information is independently developed by MIMS based on Pizotifen from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
  • Lysagor
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in